<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02653014</url>
  </required_header>
  <id_info>
    <org_study_id>KBP5074-1-002</org_study_id>
    <nct_id>NCT02653014</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects and Subjects With Renal Impairment</brief_title>
  <official_title>An Open-Label, Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects With a Separate Panel in Subjects With Mild to Moderate Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KBP Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KBP Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multiple ascending dose (MAD) study in healthy subjects and subjects with mild to&#xD;
      moderate renal impairment will evaluate the safety, tolerability and pharmacokinetics of&#xD;
      KBP-5074. Safety/tolerability data and Pharmacokinetics (PK)/Pharmacodynamics (PD) (plasma&#xD;
      aldosterone, serum potassium, UACR and Blood Pressure) relationships will be explored to&#xD;
      support the selection of dosing regimens of KBP-5074 that are suitable for the Phase II/III&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of two parts: Part 1 is an open-label, multiple ascending dose (MAD)&#xD;
      study to evaluate the safety, tolerability and pharmacokinetics of KBP-5074 in healthy&#xD;
      subjects. The safety and tolerability will be assessed at each dose level before progressing&#xD;
      to the next higher dose. Part 2 is an open label, randomized, parallel study to assess the&#xD;
      safety and tolerability, the effect of renal dysfunction on the pharmacokinetics of KBP-5074,&#xD;
      as well as the PK/PD relationship in subjects with mild to moderate renal impairment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 29, 2015</start_date>
  <completion_date type="Actual">March 28, 2017</completion_date>
  <primary_completion_date type="Actual">May 26, 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Up to 69 days</time_frame>
    <description>Rate of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (AUC) in healthy subjects</measure>
    <time_frame>pre-dose and 2, 4, 6, 8, 10, 12, 18, and 24 hours post dose on Day 1; pre-dose on Days 8, 11, 12, and 13; and pre-dose and 2, 4, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 168, 216, 264, and 312 hours post dose on Day 14</time_frame>
    <description>AUC 0-24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (AUC) in subjects with mild to moderate renal impairment</measure>
    <time_frame>pre-dose and 2, 4, 6, 8, 10, 12, 18, and 24 hours post dose on Day 1; pre-dose on Days 8, 11, 12, and 13; pre-dose and 2, 4, 6, 8, 10, 12, 18, and 24 hours post dose on Day 14; pre-dose on Days 29 and 43; and pre-dose and 6, 12, and 24 hours on Day 56</time_frame>
    <description>AUC 0-24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of mild to moderate renal impairment on the Area Under Curve (AUC)</measure>
    <time_frame>Up to 15 days</time_frame>
    <description>AUC 0-24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma aldosterone levels in healthy subjects</measure>
    <time_frame>Pre-dose, 6, and 24 hours post dose on Day 1; pre-dose on Day 8; and 24 hours post last dose on Day 15</time_frame>
    <description>Plasma aldosterone level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum potassium levels in healthy subjects</measure>
    <time_frame>Pre-dose, 6, and 24 hours post dose on Day 1; pre-dose on Day 8; and 24 hours post last dose on Day 15</time_frame>
    <description>Serum potassium level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma aldosterone levels in subjects with mild to moderate renal impairment</measure>
    <time_frame>Pre-dose, 6, and 24 hours post dose on Day 1; pre-dose on Days 8, 15, 29, and 43; and 24 hours post last dose on Day 57</time_frame>
    <description>Plasma aldosterone level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum potassium levels in subjects with mild to moderate renal impairment</measure>
    <time_frame>Pre-dose, 6, and 24 hours post dose on Day 1; pre-dose on Days 8, 15, 29, and 43; and 24 hours post last dose on Day 57</time_frame>
    <description>Serum potassium level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Albumin to Creatinine Ratio (UACR) in subjects with mild to moderate renal impairment</measure>
    <time_frame>Pre-dose, 6, and 24 hours post dose on Day 1; pre-dose on Days 8, 15, 29, and 43; and 24 hours post last dose on Day 57</time_frame>
    <description>Ratio of urinary albumin level to creatinine level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure in subjects with mild to moderate renal impairment</measure>
    <time_frame>Pre-dose, 6, and 24 hours post dose on Day 1; pre-dose on Days 8, 15, 29, and 43; and 24 hours post last dose on Day 57</time_frame>
    <description>Systolic and diastolic seated blood pressure</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy Volunteers will receive multiple dose of KBP-5074</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy Volunteers will receive multiple dose of KBP-5074</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy Volunteers will receive multiple dose of KBP-5074</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy Volunteers will receive multiple dose of KBP-5074</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with mild to moderate renal impairment will receive multiple dose of KBP-5074</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with mild to moderate renal impairment will receive multiple dose of KBP-5074</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KBP-5074</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <other_name>mineralocorticoid receptor antagonist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Part 1:&#xD;
&#xD;
          -  Healthy male or female subject&#xD;
&#xD;
          -  Are between the ages of 18 and 45 years (inclusive);&#xD;
&#xD;
          -  Body mass index (BMI) of 19 to 30 kg/m2 inclusive and body weight not less than 50 kg.&#xD;
&#xD;
        Exclusion Criteria for Part 1:&#xD;
&#xD;
          -  Clinically significant history of gastrointestinal, cardiovascular, musculoskeletal,&#xD;
             endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic,&#xD;
             immunologic, lipid metabolism disorders, or drug hypersensitivity;&#xD;
&#xD;
          -  Known or suspected malignancy;&#xD;
&#xD;
          -  Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface&#xD;
             antigen (HBsAg), or hepatitis C (HCV) antibody;&#xD;
&#xD;
          -  Positive pregnancy test result.&#xD;
&#xD;
        Inclusion Criteria for Part 2:&#xD;
&#xD;
          -  Are between the ages of 18 and 75 years (inclusive);&#xD;
&#xD;
          -  Mild to moderate chronic kidney disease (defined as estimated glomerular filtration&#xD;
             rate (eGFR) &gt; 30 and ≤89 mL/min/1.73 m2, using the modification of diet in renal&#xD;
             disease (MDRD) formula, for &gt; 3 months;&#xD;
&#xD;
          -  Proteinuria (defined as urine albumin to creatinine ratio (UACR) ≥100 mg/g and ≤3,000&#xD;
             mg/g in two mid-morning urine specimens within a month interval);&#xD;
&#xD;
          -  Subjects treated with an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin&#xD;
             receptor blocker (ARB)&#xD;
&#xD;
          -  Serum potassium≥3.3 mmol/L and ≤4.8 mmol/L;&#xD;
&#xD;
          -  Body mass index (BMI) of 19 to 40 kg/m2 inclusive and body weight not less than 50 kg.&#xD;
&#xD;
        Exclusion Criteria for Part 2:&#xD;
&#xD;
          -  Severe uncontrolled hypertension (diastolic &gt; 115 mmHg or systolic blood pressure &gt;&#xD;
             180 mmHg) at either the Screening visit or the Study Check-in Visit;&#xD;
&#xD;
          -  Type I diabetes mellitus or poorly controlled Type 2 diabetes mellitus (HbA1c &gt; 10%)&#xD;
             at the Screening visit;&#xD;
&#xD;
          -  Prior kidney transplant, or anticipated need for transplant during study&#xD;
             participation;&#xD;
&#xD;
          -  Clinical diagnosis of heart failure and persistent symptoms (New York Heart&#xD;
             Association [NYHA] Class II- IV) at either the Screening visit or the Study Check-in&#xD;
             Visit;&#xD;
&#xD;
          -  Known or suspected contraindications to study medications, including history of&#xD;
             hypersensitivity or allergy to ACE inhibitors, ARBs, or aldosterone antagonists;&#xD;
&#xD;
          -  Any clinically significant disorder, except for conditions associated with type 2&#xD;
             diabetes mellitus history, which in the investigators opinion could interfere with the&#xD;
             results of the trial;&#xD;
&#xD;
          -  Diabetic gastroparesis;&#xD;
&#xD;
          -  Known bilateral clinically relevant renal artery stenosis (&gt;75% reduction in artery&#xD;
             diameter).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fred Yang, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>KBP Biosciences USA Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research by Design, LLC</name>
      <address>
        <city>Evergreen Park</city>
        <state>Illinois</state>
        <zip>60805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>December 29, 2015</study_first_submitted>
  <study_first_submitted_qc>January 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2016</study_first_posted>
  <last_update_submitted>August 8, 2018</last_update_submitted>
  <last_update_submitted_qc>August 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mineralocorticoids</mesh_term>
    <mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>September 4, 2019</submitted>
    <returned>September 24, 2019</returned>
    <submitted>August 30, 2021</submitted>
    <returned>September 23, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

